Use and cost of disease-modifying therapies by Sonya Slifka Studyparticipants: has anything really changed since 2000 and 2009?

摘要

BackgroundDisease-modifying therapies benefit individuals with relapsing forms of multiple sclerosis, but their utility remains unclear for those without relapses.